Exploring the Therapeutic Role of CO-RMS: A Novel Perspective on Prostate Cancer Development

GASTON PASCUAL; AGUSTINA SABATER; PABLO SANCHIS; ROCIO SENIUK; JAVIER COTIGNOLA; ELBA VAZQUEZ; ROBERTO MOTTERLINI; AYELEN TORO; GERALDINE GUERON

Simposio; 12th Annual Symposium on Global Cancer Research (ASGCR).; 2024

Purpose: Carbon monoxide (CO) is recognized for its anti-inflammatory, anti-apoptotic, and anti-proliferative properties. The application of carbon monoxide-releasing molecules (CO-RMs) is thus a promising strategy for therapeutic interventions in various pathological conditions, particularly in the field of oncology. This study aims to evaluate the influence of CO-RMs on several key processes involved in the pathogenesis of prostate cancer (PCa).Methods: We assessed the effects of three water-soluble CO-RMs — CORM-3, CORM-401, and CORM-A1 (concentrations ranging from 25 to 150µM for 6 hours) — on two prostate adenocarcinoma cell lines: the androgen receptor-insensitive PC3 and the androgen receptor-dependent MDA PCa 2b. Cell viability was assessed using the MTS assay. The production of reactive oxygen species (ROS) was measured via the DCFH-DA probe by confocal microscopy. Additionally, we performed migration and cell adhesion assays and evaluated several metabolic parameters, including ATP levels by luciferase assay and lactate dehydrogenase (LDH) enzyme activity by kinetic assay. The expression of genes associated with oxidative stress, angiogenesis, and metabolism was quantified using real-time PCR. Statistical significance was predetermined at p